Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Eli Lilly Trades Up 15% on Positive Phase 3 Breast Cancer Trial Results

Eli Lilly shares set a new 52-week high price after the company reported that its Verzenio® (abemaciclib) significantly reduced the risk of cancer returning in people with high risk HR+, HER2- early breast cancer. Eli Lilly and Co. (LLY:NYSE) today annou...
Streetwise Reports | June 17, 2020 |

Myovant Sciences Shares Rise on NDA Filing for Uterine Fibroid Combination Therapy Drug

Shares of Myovant Sciences traded 40% higher after the company reported that it has submitted a New Drug Application to the FDA for once-daily relugolix combination tablet for the treatment of women with uterine fibroids. Healthcare company Myovant Sciences Ltd. (...
Streetwise Reports | June 2, 2020 |

Myovant Sciences Shares Up 110% on Phase 3 Advanced Prostate Cancer Data

Shares of Myovant Sciences opened 120% higher today after the firm reported a 97% response rate in its Phase 3 HERO Study of oral Relugolix in men with advanced prostate cancer. In the study, Relugolix achieved all six key secondary endpoints and the firm expects to submit a N...
Streetwise Reports | November 20, 2019 |

NewLink Genetics Shares Shoot Higher after FDA Ebola Vaccine Approval

Shares of NewLink Genetics got a boost today after the firm reported that the FDA approved its ERVEBO V920 vaccine used in the treatment of Zaire Ebola virus. The company's shares set a new 52-week high price in mid-morning trading. This morning after the U.S. markets...
Streetwise Reports | December 23, 2019 |

Eton Pharma Shares Climb 20% After Firm Secures US Rights for Pediatric Kidney Disease Drug

Shares of Eton Pharmaceuticals traded higher after the company reported that it has acquired U.S. marketing rights to pediatric orphan drug Alkindi® Sprinkle from Diurnal Group Plc. Eton Pharmaceuticals Inc. (ETON:NASDAQ) , which is focused on devel...
Streetwise Reports | March 30, 2020 |

Buzz on the Bullboards: Can health care and energy stocks help “recession proof” your portfolio?

Investors often keep focused on the most consistent plays, when times of renewed uncertainty rears its head in the markets. The recent wave of uncertainty follows the earlier wave, both caused by the U.S. debt ceiling deal and worries over an impending rec...
Jonathon Brown | June 1, 2023 |